--- title: "Armata Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.51 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295708484.md" datetime: "2026-08-12T20:53:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295708484.md) - [en](https://longbridge.com/en/news/295708484.md) - [zh-HK](https://longbridge.com/zh-HK/news/295708484.md) generator: "portal-rs" --- # Armata Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.51 M Revenue: As of FY2026 Q2, the actual value is USD 2.51 M, beating the estimate of USD 420 K. EPS: As of FY2026 Q2, the actual value is USD -0.27, beating the estimate of USD -0.445. EBIT: As of FY2026 Q2, the actual value is USD 80.71 M. ### Second Quarter 2026 Financial Results (Three Months Ended June 30, 2026 vs. 2025) #### Grant and Award Revenue Armata Pharmaceuticals, Inc. recognized grant and award revenue of $2.5 million for the three months ended June 30, 2026, an increase from $2.2 million in the comparable period in 2025. This revenue represents the Medical Technology Enterprise Consortium’s share of costs for the AP-SA02 program. #### Research and Development Expenses Research and development expenses were approximately $7.6 million for the three months ended June 30, 2026, compared to approximately $6.4 million for the comparable period in 2025. The increase was primarily due to higher non-cash stock-based compensation. #### General and Administrative Expenses General and administrative expenses for the three months ended June 30, 2026, were approximately $5.2 million, up from approximately $2.6 million in the comparable period in 2025, primarily due to higher non-cash stock-based compensation. #### Loss from Operations Loss from operations for the three months ended June 30, 2026, was approximately -$10.3 million, compared to a loss of approximately -$6.8 million for the comparable period in 2025. This increased loss was mainly due to higher research and development and general and administrative expenses, partially offset by higher grant and award revenue. #### Other Income (Expense), Net Other income, net, for the three months ended June 30, 2026, was approximately $84.5 million, compared with other expense, net, of approximately -$9.5 million for the comparable period in 2025. This was primarily driven by a $91.0 million non-cash gain from the change in fair value of the Convertible Loan, partially offset by -$6.6 million of interest expense. #### Net Income (Loss) Armata Pharmaceuticals, Inc. reported a net income of $74.1 million for the second quarter of 2026, significantly up from a net loss of -$16.3 million for the comparable period in 2025. ### Six Months Ended June 30, 2026 Financial Results (Six Months Ended June 30, 2026 vs. 2025) #### Grant and Award Revenue Grant and award revenue for the six months ended June 30, 2026, was $3.3 million, an increase from $2.7 million in the comparable period in 2025. #### Research and Development Expenses Research and development expenses for the six months ended June 30, 2026, were $13.7 million, compared to $11.8 million in the comparable period in 2025. #### General and Administrative Expenses General and administrative expenses for the six months ended June 30, 2026, were $8.7 million, compared to $5.9 million in the comparable period in 2025. #### Operating Loss Operating loss for the six months ended June 30, 2026, was -$19.1 million, compared to -$15.0 million in the comparable period in 2025. #### Other Income (Expense), Net Other income (expense), net, for the six months ended June 30, 2026, was -$22.1 million, compared to -$7.8 million in the comparable period in 2025. #### Net Income (Loss) Armata Pharmaceuticals, Inc. reported a net loss of -$41.2 million for the six months ended June 30, 2026, an increase from a net loss of -$22.8 million for the comparable period in 2025. ### Balance Sheet Highlights (As of June 30, 2026 vs. December 31, 2025) #### Cash and Cash Equivalents As of June 30, 2026, Armata Pharmaceuticals, Inc. held approximately $24.0 million in unrestricted cash and cash equivalents, an increase from $8.7 million as of December 31, 2025. This increase primarily reflected a $25.0 million term loan, approximately $2.4 million of net proceeds from the at-the-market offering program, and $1.2 million from stock option exercises, partially offset by cash used in operations. #### Total Assets Total assets were $89.95 million as of June 30, 2026, compared to $76.88 million as of December 31, 2025. #### Total Liabilities Total liabilities were $321.12 million as of June 30, 2026, compared to $295.48 million as of December 31, 2025. #### Total Stockholders’ Deficit Total stockholders’ deficit was -$231.17 million as of June 30, 2026, compared to -$218.60 million as of December 31, 2025. ### Cash Flow Highlights (Six Months Ended June 30, 2026 vs. 2025) #### Net Cash Used in Operating Activities Net cash used in operating activities was -$14.4 million for the six months ended June 30, 2026, compared to -$14.8 million for the comparable period in 2025. #### Net Cash Used in Investing Activities Net cash used in investing activities was -$0.08 million for the six months ended June 30, 2026, compared to -$0.25 million for the comparable period in 2025. #### Net Cash Provided by Financing Activities Net cash provided by financing activities was $28.5 million for the six months ended June 30, 2026, compared to $10.0 million for the comparable period in 2025. ### Outlook / Guidance Armata Pharmaceuticals, Inc. is finalizing activities to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated *S. aureus* bacteremia in the second half of 2026. The company recently submitted the Phase 3 protocol to the FDA and responded to the Agency’s End-of-Phase 2 meeting minutes, while also advancing manufacturing to support study initiation. Armata Pharmaceuticals, Inc. also received an additional $2.5 million in non-dilutive funding, bringing the total funding for supporting the planned Phase 3 clinical study to $28.7 million. ### Related Stocks - [ARMP.US](https://longbridge.com/en/quote/ARMP.US.md) ## Related News & Research - [Armata Advances AP-SA02 Toward Phase 3 Trial Launch](https://longbridge.com/en/news/293209036.md) - [Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment](https://longbridge.com/en/news/293234406.md) - [Why Arm Holdings stock popped today](https://longbridge.com/en/news/295832046.md) - [Major Insider Move at Eton Pharmaceuticals Shakes Up Investor Buzz](https://longbridge.com/en/news/296561958.md) - [Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295957896.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**